Expecto Health Science secures growth capital to accelerate Asia-Pacific expansion

New Delhi: Expecto Health Science, a Singapore-headquartered, Asia-focused clinical research organization (CRO), has secured strategic growth capital through a venture investment from Southern Star Research (SSR), which is backed by Quadrant Private Equity, one of Australia’s leading private equity investment firms.

The investment strengthens Expecto’s ability to scale its operations across Asia-Pacific and enhances cross-regional integration between early-phase development in Australia and later-phase execution across key Asian markets.

By combining SSR’s early-phase expertise and institutional backing with Expecto’s established operational footprint across Asia, the collaboration creates a more seamless pathway for biotech and pharmaceutical sponsors conducting clinical trials across the region.

“This growth capital represents an important milestone in Expecto’s expansion journey,” said Dr. Pramod Kashid, Founder & CEO of Expecto Health Science. “We remain focused on building a scalable, Asia-centric clinical development platform that delivers operational excellence and integrated early-to-late phase execution for global sponsors.”

Southern Star Research CEO Lloyd Prescott noted that the investment reflects long-term confidence in the Asia-Pacific clinical research ecosystem and Expecto’s growth trajectory.

Expecto Health Science will continue to operate independently as a Singapore-based CRO, maintaining its leadership team and governance structure while expanding regional capabilities.